

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 27 NOVEMBER 2024

Reference is made to the notice of the extraordinary general meeting (the “**EGM Notice**”) of PuraPharm Corporation Limited (the “**Company**”) and the circular of the Company both dated 5 November 2024. The board of directors (the “**Board**”) of the Company is pleased to announce that at the extraordinary general meeting held on Wednesday, 27 November 2024 at 11:00 a.m. (the “**EGM**”), the proposed special resolution as set out in the EGM Notice was duly passed as a special resolution, by the shareholders of the Company (the “**Shareholders**”) by way of poll. The poll results in respect of the resolution proposed at the EGM were as follows:

SPECIAL RESOLUTION		Total number of votes	Number of votes (%)	
			For	Against
1.	To approve the Capital Reduction and the Subdivision.	209,377,441	209,376,741 (99.999666%)	700 (0.00334%)

The description of the above resolution is by way of summary only. The full text of such resolution appears in the EGM Notice.

As more than 75% of the votes were cast in favour of resolution no.1, the resolution no.1 was duly passed as a special resolution of the Company.

As at the date of the EGM, the total number of issued shares of the Company was 395,897,275 shares, which was the total number of shares entitling the Shareholders to attend and vote for or against on the resolution at the EGM. There were no shares entitling the Shareholders to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and no Shareholder was required to abstain from voting at the EGM under the Listing Rules. There were no restrictions on any Shareholders casting votes on the proposed resolution at the EGM. No Shareholder had stated his/her/its intention in the circular of the Company dated 5 November 2024 to vote against or to abstain from voting on the resolution at the EGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

The following Directors attended the EGM, namely Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola, Mr. Leung Stephen Kwok Keung, Mr. Ho Kwok Wah, George and Dr. Leung Lim Kin, Simon.

UPDATE ON THE PROPOSED CAPITAL REDUCTION AND SUBDIVISION

Subsequent to the passing of the special resolution at the EGM, the Capital Reduction and the Subdivision is still subject to fulfilment of other conditions as set out in the section headed “Conditions for the Capital Reduction and the Subdivision” in the Circular. Further announcement(s) will be made by the Company to inform the Shareholders of the effective date of the Capital Reduction and the Subdivision as and when appropriate.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 27 November 2024

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.